Safety and Efficacy Of Recombinant Human Deoxyribonuclease Eye Drops In Patients With Sjogren's and Non-Sjogren Dry Eye Disease
Phase of Trial: Phase I/II
Latest Information Update: 07 Nov 2019
Price : $35 *
At a glance
- Drugs Dornase alfa (Primary)
- Indications Dry eyes; Sjogren's syndrome
- Focus Therapeutic Use
- 16 Oct 2019 Status changed from recruiting to discontinued.
- 15 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Sep 2018.
- 15 Jan 2018 Planned primary completion date changed from 1 Oct 2017 to 1 Jun 2018.